{"podcast":{"title":"The High Court Report","slug":"the-high-court-report-7304353","podcast_index_feed_id":7304353,"rss_url":"https://feeds.captivate.fm/scotus-oral-arguments/","website_url":"https://thehighcourtreport.com","image_url":"https://artwork.captivate.fm/32e133db-cc46-422f-a13c-e80534752cea/OPERATIVE-SCOTUS-THUMBNAIL.jpg","author":"SCOTUS Oral Arguments","episode_count":500,"summary":"The High Court Report makes Supreme Court decisions accessible to everyone. We deliver comprehensive SCOTUS coverage without the legal jargon or partisan spin—just clear analysis that explains how these cases affect your life, business, and community. What you get: Case previews and breakdowns, raw oral argument audio, curated key exchanges, detailed opinion analysis, and expert commentary from a practicing attorney who's spent 12 years in courtrooms arguing the same types of cases the Supreme Court hears. Why it works: Whether you need a focused 10-minute update or a deep constitutional dive, episodes are designed for busy professionals, engaged citizens, and anyone who wants to understand how the Court shapes America. When we publish: 3-5 episodes weekly during the Court's October-June term, with summer coverage of emergency orders and retrospective analysis. Growing archive: Oral arguments back to 2020 and expanding, so you can hear how landmark cases unfolded and track the Court's evolution. Your direct line to understanding the Supreme Court—accessible, thorough, and grounded in real legal expertise.**","last_synced_at":"2026-07-02T18:20:06.779164+00:00","page_url":"https://stenobird.com/podcast/the-high-court-report-7304353"},"episode":{"title":"Opinion Summary: Hikma Pharmaceuticals v. Amarin Pharma | Generic Drug Beats Patent Trap","slug":"opinion-summary-hikma-pharmaceuticals-v-amarin-pharma-generic-drug-beats-patent-trap","published_at":"2026-06-10T09:00:00+00:00","page_url":"https://stenobird.com/podcast/the-high-court-report-7304353/opinion-summary-hikma-pharmaceuticals-v-amarin-pharma-generic-drug-beats-patent-trap","show_page_url":"https://stenobird.com/podcast/the-high-court-report-7304353","url":"https://thehighcourtreport.com//opinion-summary-hikma-pharmaceuticals-v-amarin-pharma-generic-drug-beats-patent-trap","audio_url":"https://episodes.captivate.fm/episode/a7da18ae-95cc-48e7-a1f2-cfb36ad5920f.mp3","summary":"Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. | Case No. 24-889 | Docket Link: Here | Argued: 04/29/2026 | Decided: 06/04/2026 Overview: Amarin's cardiovascular drug patent faced challenge when generic maker Hikma launched a skinny-label version and marketed it through statements Amarin claimed encouraged doctors to prescribe the generic for the still-patented heart indication. Question Presented: Whether a generic drug maker's marketing statements plausibly constitute \"active steps\" inducing patent infringement under 35 U.S.C. §271(b). Posture: District Court dismissed; Federal Circuit reversed; Supreme Court reversed and remanded. Main Arguments: Petitioner (Hikma): (1) Statements fully consistent with lawful skinny-label marketing cannot constitute active inducement under §271(b); (2) Federal law mandated the label's contents, making legal compliance an obvious alternative explanation that forecloses liability; (3) The Federal Circuit's physician-reading standard would destroy the Hatch-Waxman section viii pathway and expose generics to devastating litigation risk. Respondent (Amarin): (1) Hikma's totality of statements — repeatedly invoking \"generic Vascepa,\" using an overbroad therapeutic category, and touting Vascepa's billion-dollar sales — plausibly encouraged infringing use; (2) Amarin spent $300 million discovering the cardiovascular indication and patent law must protect that investment from free-riders; (3) Seven other generic manufacturers avoided liability by accurately describing only their narrow approved uses, demonstrating Hikma's conduct fell outside normal practice. Holding: Amarin failed to state a claim for active inducement in violation of §271(b); none of Hikma's alleged statements — individually or in totality — plausibly constituted ac…","meta_description":"Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. | Case No. 24-889 | Docket Link: Here | Argued: 04/29/2026 | Decided: 06/04/2026 Overview: Amarin's…","key_points":[],"chapters":[],"topics":[],"duration_seconds":3738,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/the-high-court-report-7304353/episodes/opinion-summary-hikma-pharmaceuticals-v-amarin-pharma-generic-drug-beats-patent-trap/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/the-high-court-report-7304353/opinion-summary-hikma-pharmaceuticals-v-amarin-pharma-generic-drug-beats-patent-trap.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}